{"public_id":"cl_24da5bf57ef7324c71ee595d4805a9e4","status":"active","superseded_by_public_id":null,"corpus_id":24041837,"text":"Calcium-based phosphate binders produced significantly higher serum calcium concentrations and more frequent hypercalcemia (16% vs. 5% with sevelamer) than sevelamer.","confidence":0.9,"paper":{"corpus_id":24041837,"title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.","url":"https://sah.borca.ai/papers/24041837"},"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.9,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":3},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_a7421c33486a1c0f95b45067dcd66f0b","name":"sevelamer","description":"A non-absorbed polymer used as a phosphate-binding drug to lower serum phosphorus in hemodialysis patients.","types":["drug","phosphate binder"],"url":"https://sah.borca.ai/concepts/co_a7421c33486a1c0f95b45067dcd66f0b"},{"public_id":"co_ac2b069643378f491f8b7d6a7e0efd8d","name":"calcium-based phosphate binders","description":"Phosphate-binding medications containing calcium, used as the comparator treatment to sevelamer in this trial.","types":["drug","phosphate binder"],"url":"https://sah.borca.ai/concepts/co_ac2b069643378f491f8b7d6a7e0efd8d"},{"public_id":"co_c0e086c287b5081b9e8c8fb96e41afff","name":"hypercalcemia","description":"An abnormally elevated serum calcium concentration, tracked as an adverse outcome of phosphate-binder treatment.","types":["adverse outcome","condition"],"url":"https://sah.borca.ai/concepts/co_c0e086c287b5081b9e8c8fb96e41afff"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_24da5bf57ef7324c71ee595d4805a9e4"}